- Home
- PTGX vs IMCR Comparison
PTGX vs IMCR Comparison
Compare PTGX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- IMCR
- Stock Information
- Founded
- PTGX 2006
- IMCR 2008
- Country
- PTGX United States
- IMCR United Kingdom
- Employees
- PTGX N/A
- IMCR N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PTGX Health Care
- IMCR Health Care
- Exchange
- PTGX Nasdaq
- IMCR Nasdaq
- Market Cap
- PTGX 2.8B
- IMCR 1.7B
- IPO Year
- PTGX 2016
- IMCR 2021
- Fundamental
- Price
- PTGX $47.91
- IMCR $32.93
- Analyst Decision
- PTGX Strong Buy
- IMCR Buy
- Analyst Count
- PTGX 7
- IMCR 14
- Target Price
- PTGX $52.83
- IMCR $74.75
- AVG Volume (30 Days)
- PTGX 450.1K
- IMCR 267.8K
- Earning Date
- PTGX 11-08-2024
- IMCR 11-05-2024
- Dividend Yield
- PTGX N/A
- IMCR N/A
- EPS Growth
- PTGX N/A
- IMCR N/A
- EPS
- PTGX 2.75
- IMCR N/A
- Revenue
- PTGX $319,120,000.00
- IMCR $280,914,000.00
- Revenue This Year
- PTGX $400.33
- IMCR $25.60
- Revenue Next Year
- PTGX N/A
- IMCR $10.63
- P/E Ratio
- PTGX $17.54
- IMCR N/A
- Revenue Growth
- PTGX 125.73
- IMCR 27.95
- 52 Week Low
- PTGX $13.76
- IMCR $29.72
- 52 Week High
- PTGX $48.89
- IMCR $76.98
- Technical
- Relative Strength Index (RSI)
- PTGX 60.40
- IMCR 52.76
- Support Level
- PTGX $45.33
- IMCR $31.10
- Resistance Level
- PTGX $48.89
- IMCR $35.47
- Average True Range (ATR)
- PTGX 1.28
- IMCR 1.49
- MACD
- PTGX 0.11
- IMCR 0.17
- Stochastic Oscillator
- PTGX 77.11
- IMCR 51.98
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.